SOURCE: BIOLASE Technology, Inc.

November 28, 2005 15:17 ET

BIOLASE Reports on WCLI Symposiums

SAN CLEMENTE, CA -- (MARKET WIRE) -- November 28, 2005 -- BIOLASE Technology, Inc. (NASDAQ: BLTI), a medical technology company that develops, manufactures and markets lasers and related products focused on technologies for improved applications and procedures in dentistry and medicine, today reported on the World Clinical Laser Institute's (WCLI) symposiums.

The World Clinical Laser Institute recently held two symposiums on November 11th - 13th at the Ceylan Intercontinental Hotel in Istanbul, Turkey and Fairmont Le Chateau Frontenac Hotel in Quebec City, Canada. The mission of the institute is to provide advanced clinical laser education for dental professionals as well as training to current customers on how they can maximize the clinical, marketing and financial benefits of BIOLASE products. The WCLI is open to newcomers to the field of laser dentistry and general practitioners investigating the purchase of a laser.

Over 200 dentists attended the three-day event in Istanbul, traveling from over 28 countries around the globe. In Quebec City, more than 140 dentists attended the three-day event, including approximately 90 prospective customers. The symposiums offered a broad range of hands-on clinical training and educational seminar programs. Some of the topics covered included a presentation by Professor Andreas Moritz from Vienna, Austria, who discussed the evolution of lasers in dentistry and how Waterlase technology will evolve to be a standard of care due to its greater patient comfort and improved clinical outcomes. The symposiums provided a variety of essential support services to practicing laser dentists, including ongoing education, after-sale support and an excellent platform for current and future customers to fully investigate laser technology.


BIOLASE Technology, Inc. ( is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies for improved applications and procedures in dentistry and medicine. The Company's products incorporate patented and patent pending technologies focused on reducing pain and improving clinical results. Its primary product, the Waterlase® system, is the best selling dental laser system. The Waterlase® system uses a patented combination of water and laser to precisely cut hard tissue, such as bone and teeth, and soft tissue, such as gums, with minimal or no damage to surrounding tissue. The Company also offers the LaserSmile™ system, which uses a laser to perform soft tissue and cosmetic procedures, including tooth whitening.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors, which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

Contact Information

  • For further information, please contact:
    Robert E. Grant
    President & CEO

    John W. Hohener
    Executive Vice President and CFO

    Scott Jorgensen
    Director of Finance & Investor Relations

    BIOLASE Technology, Inc.